Glassy Mountain Advisors Inc. Acquires New Holdings in IQVIA Holdings Inc. $IQV

Glassy Mountain Advisors Inc. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 17,769 shares of the medical research company’s stock, valued at approximately $4,005,000.

Other hedge funds have also recently bought and sold shares of the company. Eubel Brady & Suttman Asset Management Inc. bought a new stake in IQVIA in the 3rd quarter valued at about $14,278,000. Eagle Rock Investment Company LLC increased its stake in IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares during the period. OPTIMAS CAPITAL Ltd acquired a new position in IQVIA during the 3rd quarter valued at about $4,008,000. EDENTREE ASSET MANAGEMENT Ltd acquired a new position in IQVIA during the 3rd quarter valued at about $7,368,000. Finally, AMG National Trust Bank acquired a new position in IQVIA during the 3rd quarter valued at about $3,713,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $182.12 on Thursday. IQVIA Holdings Inc. has a one year low of $143.00 and a one year high of $247.04. The company has a 50-day moving average of $171.35 and a two-hundred day moving average of $195.26. The stock has a market cap of $30.40 billion, a price-to-earnings ratio of 22.57, a PEG ratio of 1.73 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the company posted $2.70 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.58 earnings per share for the current year.

IQVIA announced that its board has approved a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. Jefferies Financial Group lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. HSBC set a $210.00 target price on shares of IQVIA in a research note on Wednesday. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a research note on Friday, February 6th. Mizuho set a $215.00 target price on shares of IQVIA in a research note on Monday, February 23rd. Finally, Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.